期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 22, 期 16, 页码 5303-5307出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2012.06.030
关键词
Complement inhibitors; C1s inhibitors; Pegylation; Pegylated small molecule; Polyethylene glycol-modified; Pharmacokinetics; Polyethylene glycol-modified small molecule; Pegylated molecule pharmacokinetics; Pegylated molecule PK
Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). The utility of biphenylsulfonyl-thiophene-carboxamidine small-molecule C1s inhibitors are limited by their poor in vivo pharmacokinetic properties. Pegylation of a potent analog has provided compounds with good potency and good in vivo pharmacokinetic properties. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据